The observed inhibition of NF-κB activation by erioflorin and its acetate reinforces their potential as modulators of key signaling pathways involved in cancer progression, consistent with previous research on germacrane sesquiterpene lactones and their ability to affect NF-κB activity. Here, NFKB1 is linked to cancer.